Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection.
CAMMAROTA, G.; CANNIZZARO, O. *; OJETTI, V.; CIANCI, R.; PASTORELLI, A.; ARMUZZI, A.; GENTILONI, N.; GASBARRINI, A.; PIROZZI, G.; GASBARRINI, G.
[Article] Alimentary Pharmacology & Therapeutics. 14(1):73-77, January 2000.

(Format: HTML)

Background: Ranitidine bismuth citrate (RBC)-based triple therapies for a period of 7 days have proved to be an effective treatment for Helicobacter pylori.

Aim: To investigate the eradication efficacy, safety profile and patient compliance of two RBC-based triple therapies given for 5 days.

Methods: Eighty H. pylori-positive patients with dyspeptic symptoms, referred to us for gastroscopy, were consecutively enrolled in this prospective, randomized, open-label study. These patients were randomly assigned to receive a 5-day course of RBC 400 mg b.d. plus clarithromycin 500 mg b.d. and either tinidazole 500 mg b.d. (RBCCT group) or amoxycillin 1 g b.d. (RBCCA group). The H. pylori status was assessed by means of histology and rapid urease test at entry, and by 13C-urea breath test 8 weeks after the completion of treatment.

Results: All enrolled patients completed the study. Thirty-seven of 40 patients treated with RBCCT (both PP and ITT analysis: 93%; 95% CI: 80-98%) and 35 of 40 in the RBCCA group (both PP and ITT analysis: 88%; 95% CI: 73-96%) returned H. pylori-negative. Slight or mild side-effects occurred in 4/40 patients (10%) in the RBCCT group and in 5/40 (12%) in the RBCCA group.

Conclusions: This is the first study demonstrating the efficacy of RBC-based tripie therapies given for only 5 days. RBC regimens containing high-dose clarithromycin and either amoxycillin or tinidazole prove to be well tolerated, safe and preserve good eradication rates even when administered for a shorter than conventional duration.

(C) 2000 Blackwell Science Ltd.